1. Home
  2. PLSM vs CTXR Comparison

PLSM vs CTXR Comparison

Compare PLSM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulsenmore Ltd. Ordinary Shares

PLSM

Pulsenmore Ltd. Ordinary Shares

HOLD

Current Price

$1.40

Market Cap

11.6M

Sector

Health Care

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

SELL

Current Price

$0.51

Market Cap

13.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PLSM
CTXR
Founded
2014
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
13.4M
IPO Year
2025
2010

Fundamental Metrics

Financial Performance
Metric
PLSM
CTXR
Price
$1.40
$0.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.6K
★ 253.3K
Earning Date
08-31-2026
12-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.38
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$104.18
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$0.37
52 Week High
$12.97
$1.54

Technical Indicators

Market Signals
Indicator
PLSM
CTXR
Relative Strength Index (RSI) 28.23 48.05
Support Level N/A $0.47
Resistance Level $2.64 $0.63
Average True Range (ATR) 0.12 0.06
MACD 0.00 -0.00
Stochastic Oscillator 4.65 22.42

Price Performance

Historical Comparison
PLSM
CTXR

About PLSM Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: